August 2012 in “Expert Review of Dermatology” Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.
July 2012 in “The Journal of Urology” Testosterone increases muscle mass regardless of DHT conversion blocking.
March 2012 in “Society for Endocrinology BES 2012” A new method was developed to analyze certain hormones and drugs in human blood efficiently.
February 2012 in “Expert Review of Endocrinology & Metabolism” The document suggests more research is needed to understand the link between baldness and prostate cancer.
February 2012 in “Community oncology” The document concludes that accurately identifying leukemia types is crucial, and the risks of cancer from finasteride need careful evaluation against its benefits.
February 2012 in “Community oncology” Finasteride for hair loss may increase the risk of certain cancers and has side effects; better regulation and education on its use are needed.
January 2012 in “Guangdong Medical Journal” Family history affects onset and severity of androgenic alopecia, but treatment success depends more on therapy duration.
January 2012 in “Human health handbooks” Traditional Indian remedies are used for hair health, but more scientific evidence is needed to prove their safety and effectiveness.
November 2011 in “Nature Clinical Practice Urology” 5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.
The oral testosterone effectively increased testosterone levels and reduced SHBG, showing promise for treating testosterone deficiency.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.
January 2011 in “InTech eBooks” Pesticide exposure may increase the risk of hypospadias in males.
January 2011 in “Medical Recapitulate” 5α-reductase enzyme affects hormone levels, influencing conditions like acne and hair loss.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
August 2010 in “The Journal of urology/The journal of urology” Male pattern baldness may be linked to prostate cancer risk.
Androgens reduce macrophage receptor expression, affecting immune response, while antiandrogens counteract this effect.
March 2010 in “Gynecologic and Obstetric Investigation” Hirsutism in women can be a cosmetic issue or a sign of hormonal imbalance, treatable with hormonal and cosmetic methods.
January 2010 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride may be a promising treatment for recurrent priapism in sickle cell anemia.
January 2010 in “Elsevier eBooks” Hair transplantation is a treatment for hair loss mainly caused by genetics, with various techniques and potential complications, and results visible after 8-12 months.
September 2009 in “European Urology Supplements” After prostate removal surgery, higher initial prostate size was linked to higher urethral PSA levels and more severe male pattern baldness.
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
Finasteride significantly reduces the risk of prostate cancer.
March 2009 in “The Journal of Urology” Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.
March 2009 in “The Journal of Urology” Finasteride helps treat hair loss and prostate issues by blocking a hormone.
February 2009 in “RePub (Erasmus University Rotterdam)” Androgen receptor activity is influenced by hormones, co-factors, modifications, and mutations.
January 2009 in “Acta urologica Belgica” Finasteride effectively treats BPH by reducing prostate size and improving symptoms.
November 2008 in “Medical Hypotheses” The conclusion suggests a new treatment for infantile hemangiomas and a potential target for hair loss treatment.
Finasteride reduces DHT to treat prostate issues and hair loss.